SELECT2: A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke

Acute Ischemic Stroke Clinical Trial

— SELECT2  

Official title:

SELECT2: A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03876457
• Other study ID #: G180275, Pro00056862
• Status: Completed
• Phase: N/A
• Start date: October 11, 2019
• Est. completion date: November 16, 2023

Study information

• Verified date: February 2024
• Source: University Hospitals Cleveland Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

SELECT 2 evaluates the efficacy and safety of endovascular thrombectomy compared to medical management alone in acute ischemic stroke patients due to a large vessel occlusion in the distal ICA and MCA M1 who have large core on either CT (ASPECTS: 3-5) or advanced perfusion imaging ([rCBF<30%] on CTP or [ADC<620] on MRI: ≥50cc) or both and are treated within 0-24 hours from last known well.

Description:

SELECT 2 is a prospective, phase III randomized, international, multicenter, assessor-blinded controlled trial evaluating the efficacy and safety of thrombectomy in patients with large core on either CT or advanced perfusion imaging treated within 0-24 hours from last known well.

Patients with the final diagnosis of an acute ischemic stroke due to a large vessel occlusion in the distal ICA and MCA M1 who have large core on either CT (ASPECTS: 3-5) or advanced perfusion imaging ([rCBF<30%] on CTP or [ADC<620] on MRI: ≥50cc) or both within 0-24 hrs from last known well will be randomized in a 1:1 ratio into thrombectomy plus medical management vs medical management alone. Patient outcomes will be measured at baseline, 24 hours post, discharge, 30 days and 90 days.

The primary endpoint is the Modified Rankin Scale (mRS) at 90 (+/- 15) days. The primary outcome is a shift on 90-day mRS. Secondary outcomes are favorable clinical outcomes: mRS score of 0-2, safety outcomes such the incidence of symptomatic intracranial hemorrhage (sICH per SITS-MOST) and Imaging endpoints such as infarct volume on MRI diffusion-weighted imaging (DWI) sequence (or CT if MRI not feasible) 24 to 72 hours after randomization. CT images will be read by iSchemaView automated ASPECTS as well as by a physician. In cases where there is disagreement, the physician reading will override the automated software reading. CT/MR perfusion images with mismatch determination will be read by iSchemaView automated RAPID software. All the images will be adjudicated by a blinded core lab at the University of Texas-Medical School at Houston.

A maximum of 560 patients will be randomized across the study sites. Covariate adaptive randomization will be used to balance the distribution of important variables. Interim analyses will be conducted at 200 and 380 patients, at which time the study may stop for efficacy or futility.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 352
• Est. completion date: November 16, 2023
• Est. primary completion date: November 20, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Adults (18-85 years) with the final diagnosis of an acute ischemic stroke

2. NIH Stroke Scale Score (NIHSS) = 6

3. Last known well to groin puncture or medical management between 0 to 24 hours

4. Pre-stroke modified Rankin Scale score (mRS) of 0-1

5. Eligible for thrombectomy or medical management

6. Signed Informed Consent obtained

7. Subject willing to comply with the protocol follow-up requirements

8. Anticipated life expectancy of at least 3 months

Specific Neuroimaging Inclusion Criteria:

1. Proven large vessel occlusion in ICA or MCA-M1 occlusion (carotid occlusions can be cervical or intracranial, with or without tandem MCA lesions) determined by MRA or CTA

2. Large infarct-core lesion on at least one of the following:

• 2.1. Non-Contrast CT (ASPECTS of 3-5),

• 2.2. CT perfusion (rCBF<30% =50cc),

• 2.3. MRI-DWI (ADC<620 =50cc)

Exclusion Criteria:

1. Inability to undergo CT angiography and/or CT perfusion imaging (e.g., renal insufficiency, iodine/contrast allergy)

2. Co-morbid psychiatric or medical illnesses that would confound the neurological assessments

3. Treatment with thrombolytic agent beyond 4.5 hours from last known well

4. Treated with thrombolytic agent 3-4.5 hours after last known well AND any of the following:

• 1) age >80,

• 2) current anticoagulant use,

• 3) history of diabetes AND prior stroke,

• 4) NIHSS >25,

• 5) ischemic involvement of > 1/3 MCA territory

5. Current participation in another investigational drug or device study.

Neuroimaging Exclusion Criteria

1. Patients who have both ASPECTS of 6-10 on non-contrast CT AND core volume <50 cc on perfusion imaging

2. Patients with very large core on non-contrast CT i.e. ASPECTS = 2

3. Evidence of intracranial tumor (except small meningioma), acute intracranial hemorrhage, neoplasm, or arteriovenous malformation

4. A significant mass effect with midline shift

5. Evidence of internal carotid artery dissection that is flow limiting or aortic dissection

6. Intracranial stent implanted in the same vascular territory that precludes the safe deployment/removal of the neurothrombectomy device

7. Acute symptomatic arterial occlusions in more than one vascular territory confirmed on CTA/MRA (e.g., bilateral MCA occlusions, or an MCA and a basilar artery occlusion).

8. Signs of established infarct and large area of cerebral edema on non-contrast CT

Related Conditions & MeSH terms

• Acute Ischemic Stroke
• Cerebral Infarction
• Ischemia
• Ischemic Stroke
• Stroke

Intervention

Device:
• Endovascular Thrombectomy
Patients randomized to endovascular thrombectomy arm will receive thrombectomy plus medical management. They will be treated with thrombectomy devices (stent-retrievers or aspiration devices) currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke within 24 hours of symptom onset. The devices which will be used are FDA-approved stent retrievers: the Trevo Retriever, the Solitaire Revascularization Device, EmboTrap Revascularization Device and Tigertriever Revascularization Device; and/or the aspiration devices approved by the FDA (e.g. MicroVention SOFIA Catheter, and the Penumbra thrombectomy system). The choice of thrombectomy method, primary approach/technique, whether primary aspiration or primary stent-retriever with or without aspiration, will be left up to the interventionalist, with any of the FDA-approved devices approved in the study protocol or a combination of them.

Other:
• Medical Management
Patients will receive standard AHA guideline-directed medical therapy, which will include IV thrombolytic therapy available for use according to practice guidelines in patients presenting within the first 3 hours from last-seen-normal and meeting other FDA label criteria, or up to 4.5 hours from last-seen-normal and meeting other AHA guidelines. For non-thrombolysis treated patients, this will include aspirin 325 mg on day 1 followed by aspirin 81 mg or 325 mg thereafter, which will be determined by treating physician and standard deep venous thrombosis prevention therapy. Intravenous anticoagulation and dual anti-platelet therapy will be discouraged without clear documented reasoning. Post-thrombolysis patients will be treated based on standard study site protocols for these patients.

Locations

Country	Name	City	State
Australia	The Royal Adelaide Hospital (RAH)	Adelaide	South Australia
Australia	Liverpool Hospital - South Western Sydney Clinical School	Liverpool	New South Wales
Australia	Royal Melbourne Hospital	Melbourne	Victoria
Canada	University of Alberta	Edmonton	Alberta
Canada	University Health Network - Toronto Western Hospital	Toronto	Ontario
New Zealand	Christchurch Hospital	Christchurch	Canterbury
Spain	Hospital Universitario Germans Trias i Pujol	Badalona
Spain	Hospital Clínic i Provincial de Barcelona	Barcelona
Spain	Hospital Universitari de Bellvitge	Barcelona
Spain	Hospital Universitari Vall d'Hebron	Barcelona
Spain	Hospital Clínico Universitario de Valladolid	Valladolid
Switzerland	Universität Basel	Basel
United States	Abington Jefferson Health	Abington	Pennsylvania
United States	Dell Seton Medical Center at the University of Texas at Austin	Austin	Texas
United States	Rush University Medical Center	Chicago	Illinois
United States	Cleveland Clinic Foundation	Cleveland	Ohio
United States	University Hospitals Cleveland Medical Center	Cleveland	Ohio
United States	Riverside Methodist Hospital - OhioHealth	Columbus	Ohio
United States	Spectrum Health Hospital	Grand Rapids	Michigan
United States	Valley Baptist Medical Center	Harlingen	Texas
United States	The University of Texas Health Science Center at Houston	Houston	Texas
United States	Ascension St. Vincent Hospital	Indianapolis	Indiana
United States	University of Iowa Hospitals and Clinics	Iowa City	Iowa
United States	Baptist Health	Jacksonville	Florida
United States	University of Kansas Medical Center	Kansas City	Kansas
United States	Kaiser Permanente	Los Angeles	California
United States	Semmes Murphey Clinic - University of Tennessee Health Science Center	Memphis	Tennessee
United States	Ascension Wisconsin	Milwaukee	Wisconsin
United States	The Hospital of the University of Pennsylvania	Philadelphia	Pennsylvania
United States	Thomas Jefferson University Hospital	Philadelphia	Pennsylvania
United States	Westchester Medical Center	Valhalla	New York

Sponsors (3)

Lead Sponsor	Collaborator
University Hospitals Cleveland Medical Center	Stryker Neurovascular, The University of Texas Health Science Center, Houston

Countries where clinical trial is conducted

United States,  Australia,  Canada,  New Zealand,  Spain,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Infarct Volume on MRI DWI Sequence (or CT if MRI Not Feasible) 24 Hours to 7 Days After Randomization		24 hours to 7 days
Other	Lesion Growth Between the Ischemic Core on Baseline Imaging and the Follow-up Infarct Volume		24 hours to 7 days
Other	Number of Participants Who Suffered Parenchymal Hemorrhage Type 2		24 hours
Other	Number of Participants Who Suffered a Subarachnoid Hemorrhage		24 hours
Other	Number of Participants Who Had a Hemicraniectomy During Index Hospitalization		day 5-7 after randomization/at discharge (whichever is later)
Other	Length of Hospital Stay	Was assessed if the patient was discharged at every follow-up visit to determine the length of the stay if the patient was not discharged at the time of previous follow-up visit.	Up to 90-day follow up visit
Primary	Degree of Disability/Dependence as Measured by the Modified Rankin Scale (mRS) Score	The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6 with "0" being perfect health without symptoms to "6" being death.; Score 0: No symptoms Score 1: No significant disability. Able to carry out all usual activities, despite some symptoms.; Score 2: Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.; Score 3: Moderate disability. Requires some help, but able to walk unassisted. Score 4: Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.; Score 5: Severe disability. Requires constant nursing care and attention, bedridden, incontinent.; Score 6: Dead	90 days
Secondary	Number of Participants That Achieved Functional Independence as Measured by a mRS Score of 0-2 at 90-day Follow-up	The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6 with "0" being perfect health without symptoms to "6" being death.; Score 0: No symptoms Score 1: No significant disability. Able to carry out all usual activities, despite some symptoms.; Score 2: Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.; Score 3: Moderate disability. Requires some help, but able to walk unassisted. Score 4: Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.; Score 5: Severe disability. Requires constant nursing care and attention, bedridden, incontinent.; Score 6: Dead	90 days
Secondary	Number of Participants That Achieved Independent Ambulation as Measured by a mRS Score of 0-3 at 90-day Follow-up	The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6 with "0" being perfect health without symptoms to "6" being death.; Score 0: No symptoms Score 1: No significant disability. Able to carry out all usual activities, despite some symptoms.; Score 2: Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.; Score 3: Moderate disability. Requires some help, but able to walk unassisted. Score 4: Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.; Score 5: Severe disability. Requires constant nursing care and attention, bedridden, incontinent.; Score 6: Dead	90 days
Secondary	Number of Patients That Suffered a Symptomatic Intracranial Hemorrhage (sICH) as Measured by the SITS-MOST Criteria		24 hours
Secondary	Number of Participants With Neurological Worsening Defined as a =4-point Increase on the NIHSS Score Due to the Stroke Itself		24 hours
Secondary	Number of Mortalities Within 90-day Follow-up		90 days
Secondary	Number of Procedural Complications	The following were included in the complications counted: Surgical site hematoma; Surgical site infection; Vascular injury (peripheral or intracranial dissection, perforation or others) caused by the endovascular procedure	24 hours
Secondary	Successful Reperfusion in the EVT Group, Defined as Modified Thrombolysis in Cerebral Ischemia (mTICI) Grade of 2b or Higher		at the end of endovascular thrombectomy procedure
Secondary	Discharge Location		day 5-7 after randomization/at discharge (whichever is later)
Secondary	Number of Participants That Showed Early Neurological Improvement, Defined as Improvement of =8 Points on NIHSS at 24 Hours of Presentation or an NIHSS of 0-1		24 hours
Secondary	Quality of Life Score, as Measured Using NeuroQOL at 90-day Follow-up	The Neurological Quality of Life score (NeuroQoL) is a patient-reported outcome measure that assesses the impact of neurological disorders on various aspects of a person's quality of life in neurological diseases and has measures developed across 17 different domains. The trial measured NeuroQoL scores for Mobility, Depression, Social and Cognitive domains. The scores provide a measure of an individual's quality of life in a given domain relative to a reference population, with a mean score of 50 and range of 0-100. A t-score of 50 indicates average quality of life, while scores above 50 indicate better-than-average quality of life and scores below 50 indicate poorer-than-average quality of life, except for depression domain - where lower scores indicate better and higher scores indicate worse quality of life.	90 days
Secondary	The 1-year Functional Outcome, as Measured by the Modified Rankin Scale Score		1 year
Secondary	Functional Independence, Defined as mRS Score of 0-2 at 1-year Follow-up		1 year
Secondary	Independent Ambulation, Defined as mRS Score of 0-3 at 1-year Follow-up		1 year
Secondary	Quality of Life Score, as Measured Using NeuroQOL at 1 Year Follow-up		1 year